FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
Source : IMS Q2’07
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
Following is the brief report highlighting the developments in the local
pharmaceutical market including highlights of SPIMACO performance. All
information are based on IMS Quarterly reports unless otherwise indicated.
The report covers Private Market unless otherwise stated.
Sales & Marketing Department
HIGHLIGHTS: -
•Total sales of the market is SR 5,783 Millions with a growth of +9.4%
•Top ten manufacturers constitute 45.9% of Saudi Pharma (Private) Market
•Spimaco growth is 7.6% with 2nd position in Saudi Pharma (Private) Market
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
S.R MILL
700 13.7%
9
Leading Manufacturers
600
Spimaco sales consists of own products
500 7.6%
9.8%
400 <---- Grow th
300 17.5% -1.3% 7.1% 1.0%
63.0% 3.1%
200 -8.6%
100
0
Astrazenec
GSK Spimaco Pfizer Tabuk Novartis P Julphar Jamjoom Abbott Janssen
a
Rank 1 2 3 4 5 6 7 8 9 10
SR. Mill. 602 416 375 220 197 184 183 177 151 150
Mkt Share 10.4% 7.2% 6.5% 3.8% 3.4% 3.2% 3.2% 3.1% 2.6% 2.6%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
S.R MILL
700 13.7%
5.2% Leading Manufacrurers Spimaco sales
9
600 <---- Grow th includes Licensors' products
500
9.8%
400
300 17.5% -1.3% 7.1% 1.0% 63.0% 3.1% -8.6%
200
100
0
Astrazenec
GSK Spimaco Pfizer Tabuk Novartis P Julphar Jamjoom Abbott Janssen
a
Rank 1 2 3 4 5 6 7 8 9 10
SR. Mill. 602 550 375 220 197 184 183 177 151 150
Mkt Share 10.4% 9.5% 6.5% 3.8% 3.4% 3.2% 3.2% 3.1% 2.6% 2.6%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
120 12.6%
100 22.0%
Leading products by value
<---- Growth
S.R MILL
80
6.4%
60 -9.4% 12.4%
-8.56%
19.3% -1.1% 17.0% -0.1%
40
20
0
Augmentin Viagra Snafi Lipitor Rofenac Voltaren Klavox Zithromax Nexium Dermov
Rank 1 2 3 4 5 6 7 8 9 10
SR. Mill. 112 95 63 58 49 48 46 45 45 44
Mkt Share % 1.9% 1.6% 1.1% 1.0% 0.9% 0.8% 0.8% 0.8% 0.8% 0.8%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
7
3.7%
6
7.7% -0.1%
Leading products by Units
<---- Grow th
5
Unit Mill
4 24.9
% 9.7%
17.0% 24.1%
3 15.8% 14.4% 17.2%
2
1
0
Fevadol Panadol Dermov Panadol E Tylenol Ventolin Otrivin Flutab Neorobion Rofenac
Rank 1 2 3 4 5 6 7 8 9 10
Unit Mill. 6.4 5.7 5.6 3.6 3.1 2.8 2.8 2.7 2.7 2.3
Mkt Share % 2.3% 2.1% 2.0% 1.3% 1.1% 1.0% 1.0% 1.0% 1.0% 0.8%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
S.R Mill
60
55
Products contribution upto 90% of SPIMACO
50
45
40
sales in Pvt. Market
35
30
25
20
15
10
5
0
Rof Fev Cipr Kaf Fusi Lori
Sna Klav Flut Sap Fero Diat Fev Pept Fero Prot Fero Hym Zim Neo Lori Exyli Hist Exyli
ena adol oma ose der nas
fi ox ab ofen se-F ab adol azol se on sac ox ax rin ne n op nP
c SF x d m e
Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
S.R Mill 63 49 46 20 18 14 14 14 13 12 12 11 11 11 10 9 7 7 6 6 6 6 5 3
%Gr 6% 12% 19% 16% 25% -9% 4% 12% 4% 17% 5% 23% 20% 15% 25% 24% 155 -7% 16% 22% 16% -12% 65% 19%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
100%
90% Spimaco Equity Share in its Top-10 Therapeutic
80%
70% Group
60%
50%
40%
30%
20%
10%
0%
Haemat. N.Nar
Cold Antihistam Antirheum Br.Sp. Oral A- Antiulcera Total
Iron & Erect.Dys Analgesic Macrolide
Preps. ines Sys atic N.St Penicilling Diabt nts Equity
Comb. s
Mkt S.R Mill 37 23 63 20 33 59 57 19 23 10 3,169
% Share 87.4% 54.4% 30.2% 18.8% 17.8% 17.6% 16.6% 10.9% 8.1% 7.5% 13.1%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
Local Manufacturers Others
S.R Mill = 923, 16%
S.R Mill = 4850, 84%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private) Local Manufacturers
S.R MILL
450 5.6%
SPIMACO among local Manufacrurers
400
350
300
250
16.2% <---- Grow th
200
150
-3.5% 18.6% 46.0%
100
36.5%
50
0
Spimaco Tabuk Jazeera Ph. Jamjoom Ph. Riyadh Ph. Saja Ph.
Rank 1 2 3 4 5 6
SR. Mill. 416 120 177 97 75 38
Mkt Share 40.6% 21.5% 17.3% 9.5% 7.4% 3.7%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private) Local Manufacturers
70
6.4% Local manufacturers' leading
60
12.4% products by value
19.3
50
<---- Growth
S.R MILL
40
30
15.8
18.2 24.9 76.6
40.9
30.2 3.5
20
10
0
Snafi Rofenac Klavox Megam Flutab Sapofen Ciproxen Mentex Omnicef Rapidus
Rank 1 2 3 4 5 6 7 8 9 10
SR. Mill. 63 49 46 21 20 18 18 17 16 15
Mkt Share % 6.1% 4.8% 4.5% 2.1% 2.0% 1.8% 1.8% 1.7% 1.6% 1.4%
FLASH SALES REPORT– Q2'2007
Saudi Pharma Market (Private)
HIGHLIGHTS:
•With licensors' products, difference between no.1 GSK and SPIMACO in
terms of market share is 0.9%. By value the difference is of 52.0 Million only.
•SPIMACO sales grew by SR 29.2 Mill. Major contributors are as follows:
PRODUCTS CONT. IN MILL
KLAVOX 7.5
ROFENAC 5.4
SNAFI 3.8
SAPOFEN 3.7
FLUTAB 2.7
PEPTAZOL 1.8
DIATAB 1.6
FEVADOL S.F. 0.6
FEVADOL 0.5
By unit Fevadol, Flutab and Rofenac are at 1st, 8th and 10th positions respectively.
By value rank of Snafi, Rofenac and Klavox are 3rd, 5th and 7th likewise.